Stock listing: The company’s common shares are listed and traded on the OTCQB Venture Market in the United States under the symbol LXXGF, and in Canada on the TSX Venture Exchange under the symbol LXG.
Currency: LexeGene reports its financial results in Canadian dollars, which is the functional currency of the company.
Share Structure and Capital
| As of 13 March 2017 | |
|---|---|
| Shares Outstanding | 49,460,423 |
| Warrants Outstanding | 11,246,363 |
| Options - To be granted (Ave. Price $0.34 CAD) | 2,175,000 |
| Fully Diluted Market Capital (62,881,786 Shares @ $0.78 CAD) | $49.0 M CAD |
| Treasury | $2.8 M CAD |
Financials
| 2017 Downloads |
|---|
| Financial Statements for the period ending February 28, 2017 |
| Management Discussion and Analysis for the period ending February 28, 2017 |
Investor inquiries
Daryl Rebeck | President, LexaGene
T: 1.800.215.1824
E: darylrebeck@lexagene.com
Auditors
Dale Matheson Carr-Hilton Labonte LLP
1500 – 1140 West Pender St.
Vancouver, BC
Canada V6E 4G1
Attorneys
McMillan LLP
Royal Centre, 1055 West Georgia Street
Suite 1500, PO Box 11117
Vancouver, BC
Canada V6E 4N7
Contact: Desmond Balakrishnan